Cannabis Use during Pregnancy and Risk of Adverse Birth Outcomes: A Longitudinal Cohort Study by Gabrhelik, Roman et al.
Research Article
Eur Addict Res
Cannabis Use during Pregnancy  
and Risk of Adverse Birth Outcomes:  
A Longitudinal Cohort Study
Roman Gabrhelík a    Milada Mahic b    Ingunn Olea Lund b    Jørgen Bramness b    
Randi Selmer b    Eva Skovlund b, c    Marte Handal b    Svetlana Skurtveit b, d
aDepartment of Addictology, First Faculty of Medicine, Charles University, Prague, Czech Republic; bNorwegian 
Institute of Public Health, Oslo, Norway; cDepartment of Public Health and Nursing, Norwegian University of Science 
and Technology, Trondheim, Norway; dNorwegian Centre for Addiction Research, University of Oslo, Oslo, Norway
Received: March 18, 2020
Accepted: July 25, 2020
Published online: October 9, 2020
Roman Gabrhelík
Department of Addictology, Charles University, First Faculty of Medicine
Apolinářská 4
120 00 Prague 2 (Czech Republic) 
roman.gabrhelik @ lf1.cuni.cz 
© 2020 The Author(s)





Cannabis · Pregnancy · Birth outcome · MoBa · Prospective ·  
Cohort
Abstract
Background: With recent changes in legislation regulating 
recreational and medical cannabis use around the globe, in-
creased use in pregnancy is to be expected. Objectives: To 
investigate the association between cannabis use during 
pregnancy and birth outcomes. Method: Data from the Nor-
wegian Mother and Child Cohort Study (MoBa), a prospec-
tive pregnancy cohort, were used. Participants were recruit-
ed from all over Norway between 1999 and 2008: 9,312 
women with 10,373 pregnancies who reported use of can-
nabis before or in pregnancy. Women reported on their ille-
gal drug use before pregnancy and at pregnancy weeks 
17/18 and 30 and at 6 months postpartum. Linear regression 
was used to estimate crude and adjusted effects of prenatal 
cannabis exposure on birth outcomes. Results: In 10,101 
pregnancies, women had used cannabis before pregnancy 
but not during pregnancy. In 272 pregnancies, women had 
used cannabis during pregnancy, and among these, in 63 
pregnancies, women had used cannabis in at least 2 periods. 
In adjusted analyses for potential confounders, only canna-
bis use during at least 2 periods of pregnancy showed statis-
tically significant effects on birth weight. The effect was ob-
served in the complete cohort (B = −228 g, 95% CI = −354 to 
−102, p < 0.001) and for the subgroup where information 
about the child’s father was available (B = −225 g, 95% CI = 
−387 to −63, p = 0.01). Our results may indicate that pro-
longed use causes more harm, whereas short-term use did 
not indicate adverse effects on birth outcomes. Conclusions: 
There was a statistically significant and clinically relevant as-
sociation between the use of cannabis during pregnancy 
and reduced birth weight. Clinicians should screen not only 
for cannabis use but also for the length and intensity of use 
as part of a comprehensive substance use screening.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Cannabis is one of the most frequently used recre-
ational drugs in the world, with a yearly prevalence from 
1 to 9% in different countries, with highest use in adoles-
cents and young adults [1]. While men tend to use the 
drug more frequently and become addicted more often 
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than women [2], female use is increasing [3]. Rates of can-
nabis use among pregnant women are increasing just as 
fast as among nonpregnant women of reproductive age 
[4]. In 2015, the American College of Obstetricians and 
Gynecologists issued a committee opinion discouraging 
physicians from suggesting use of cannabis during pre-
conception, pregnancy, and lactation.
With changes in legislation regulating recreational 
cannabis use around the globe in the last decade, in-
creased use is to be expected [5, 6]. The changing public 
discourse may also support the tendency to view canna-
bis as a relatively safe drug [7]. Furthermore, cannabis is 
also used as a medication to pregnant women [8, 9], 
which might contribute to the drug seeming more harm-
less and to increased use [10]. Contemporary cannabis 
products contain more ∆-9-tetrahydrocannabinol than 
the products previously studied [11] and may infer a 
higher risk of adverse effects. With the increasing use of 
higher potency cannabis, there is a need for new research 
for public health policies to provide evidence-based ad-
vice about risks associated with cannabis use during 
pregnancy.
Most women quit using cannabis when they get preg-
nant [12], but about 3–4% of pregnant women in the US 
and southern Europe have reported cannabis use in preg-
nancy [13, 14]. In general, women who do not abstain 
from cannabis in pregnancy are also engaged in other 
risky behaviors such as alcohol and tobacco use [12]. 
Cannabis use during pregnancy raises concerns because 
prenatal cannabis exposure may be associated with ad-
verse birth outcomes [15–19]. Some studies have demon-
strated decreased birthweight and/or fetal growth after 
cannabis exposure while others have failed to find such 
differences [13, 18]. Referring to another systematic re-
view and meta-analysis [20], adverse birth outcomes as-
sociated with maternal cannabis use appear to be attribut-
able to concomitant tobacco use and other confounding 
factors. Adjustment for tobacco and other confounding 
factors was not performed in the meta-analysis by Gunn 
et al. [15]. In the “Generation R” Study, data on fetal 
growth obtained by ultrasounds showed that cannabis 
use during pregnancy was associated with growth restric-
tions in mid- and late pregnancy [21]. Furthermore, a me-
ta-analysis [15] concluded that infants exposed in utero 
to cannabis had lower birth weight, but not shorter birth 
length or smaller head circumference. Similarly, studies 
of the association between cannabis use and preterm 
birth have shown mixed results [17, 22]. Current evidence 
does not suggest an association between cannabis expo-
sure and any specific congenital birth defect, while data 
regarding the association between stillbirth and cannabis 
use are still scarce [17].
Most of the studies mentioned above have limitations. 
Earlier studies on cannabis and birth outcomes have been 
retrospective and did not possess information about im-
portant confounders such as mental health problems, so-
cioeconomic and educational factors and have not been 
able to adjust for use of other substances including to-
bacco, alcohol, other illicit or prescribed drugs [19]. Fur-
ther, in most studies, information about paternal charac-
teristics or relevant comparison groups is not included. 
However, recent research suggests that regular use of can-
nabis in men causes epigenetic changes in sperm cells 
[23], and paternal cannabis use during pregnancy has, 
potentially, further epigenetic effects [24]. Studying ef-
fects of paternal cannabis use during pregnancy is en-
couraged [25].
When studying the possible adverse effects of prenatal 
cannabis use on children, it is an advantage to include a 
relatively large and homogeneous population and to be 
able to control for polysubstance use and other confound-
ing factors. In the current study, we used data from the 
Norwegian Mother and Child Cohort Study (MoBa), a 
large prospective population-based pregnancy cohort 
with information from both parents [26, 27]. We aimed 
to describe the sociodemographic characteristics of wom-
en who used cannabis during pregnancy and assess if 
there is an association between cannabis use during preg-
nancy and adverse birth outcomes. We compared chil-
dren of women who used cannabis during pregnancy 
with children of previous users of cannabis in unadjusted 
analyses and models adjusted for important confounders.
Materials and Methods
The Norwegian Mother and Child Cohort Study
MoBa is a population-based pregnancy cohort study conducted 
by the Norwegian Institute of Public Health. Participants were re-
cruited from all over Norway from 1999 to 2008. The women con-
sented to participation in 41% of the pregnancies. The cohort now 
includes 114,500 children, 95,200 mothers, and 75,200 fathers. The 
invited women reported by responding to questionnaires at gesta-
tional weeks 17/18 and 30 and 6 months postpartum. Information 
from fathers was obtained at week 17/18 of pregnancy. Some of the 
information in MoBa was obtained from the Medical Birth Registry 
of Norway (MBRN), a national health registry containing informa-
tion about all births in Norway [28]. It includes information on 
pregnancy, delivery, and neonatal health. The attending physician 
and midwife collected medical information during delivery, which 
is recorded in the MBRN. All MoBa questionnaires are available at 
the Norwegian Institute of Public Health’s website (https://www.
fhi.no/en/sys/search-result/?term=MoBa+questionnaires#).





This study was based on data from pregnant women who par-
ticipated in MoBa and their children (data file version 8). Children 
from pregnancies with multiple fetuses and pregnancies with in-
complete questionnaires when cannabis use in pregnancy was to 
be reported were excluded. After exclusion, the population con-
sisted of 74,641 pregnancies in 65,412 women. Women who had a 
history of cannabis use may differ from women who never used 
cannabis regarding many risk factors. A comparison between “use 
during pregnancy” versus “never use” could thus be biased due to 
unmeasured confounding. In order to reduce this problem, in our 
analyses, we included only pregnancies where women reported use 
of cannabis before pregnancy and/or during pregnancy. The study 
population hence consisted of 9,312 women with 10,373 pregnan-
cies. The study was approved by the Regional Committee for Med-
ical Research Ethics (2015/1343).
Self-Report of Cannabis Use
The women answered questions regarding illegal drug use at 
pregnancy weeks 17/18 and 30 and 6 months postpartum. The 3 
questionnaires covered use earlier in life, use during the last month 
before pregnancy, use during 3 time periods during pregnancy 
(before week 17/18, between weeks 17/18 and 30, and after week 
30), and use after birth. The women provided information about 
their hashish, amphetamine, ecstasy, cocaine, and heroin use dur-
ing these time periods. The use of cannabis was defined as use of 
hashish since in Norway hashish was traditionally the only canna-
bis product available.
The use of cannabis during 1 period was defined as curtailed 
use, and the use of cannabis during 2 or more periods was defined 
as prolonged use. The use of cannabis earlier in life or last month 
before pregnancy but not during pregnancy was defined as previ-
ous use.
Birth Outcomes
Information on birth weight, birth length, head circumference, 
preterm birth (<37 weeks of gestation), malformations, and Apgar 
score after 1 and 5 min was obtained from the MBRN. Small for 
gestational age was calculated after Marsál et al. [29]. The length 
of pregnancy was mainly determined from the estimated pregnan-
cy start date based on ultrasound. For pregnancies in which no 
ultrasound was performed, the start of pregnancy was set to the 
first day of the last menstrual period.
Possible Confounders, Mediators, and Effect Modifiers
Information on factors that could be associated with cannabis 
use during pregnancy, for example, maternal age, marital status, 
parity, and body mass index (kg/m2), was retrieved from the 
MBRN. Information about the level of education, whether the 
pregnancy was planned, and the working status during pregnancy 
was retrieved from the first pregnancy questionnaire. The 5-item 
version of the Hopkins Symptom Checklist (HSCL-5 of the HSCL-
90) was used to assess symptoms of anxiety or depression. A de-
scription of the assessment has been described elsewhere [30]. 
Symptoms of anxiety or depression were assessed during pregnan-
cy weeks 17/18 and 30. In the first questionnaire, mothers also re-
ported on their lifetime history of major depression by answering 
the lifetime occurrence of 5 key depressive symptoms from the 
symptomatic criteria for Major Depression in the Diagnostic and 
Statistical Manual of Mental Disorders [30]. The two pregnancy 
questionnaires and the 6-month postpartum questionnaire also 
included questions on other substance use during pregnancy: to-
bacco smoking, alcohol intake, and use of prescribed opioids and 
benzodiazepines and illegal drugs other than cannabis. The moth-
ers’ answer on all the 3 questionnaires were used to categorize all 
these variables. Tobacco smoking during pregnancy was catego-
rized as no, sometimes, and daily. To fall into the no tobacco use 
group, the woman had to respond not smoking in all three ques-
tionnaire periods. Similarly, to be considered a daily smoker, the 
woman had to answer daily smoking in all three questionnaire pe-
riods. All remaining women who responded smoking at any time 
comprised the sometimes group. Alcohol intake during pregnancy 
was categorized as never, sometimes, and regular/binge. To be de-
fined as a pregnant woman who never used alcohol, the woman 
must have answered never using alcohol in all three questionnaire 
periods. To be defined in the regular/binge group, the woman had 
to report drinking regularly or drinking 5 units or more on one 
occasion in at least one of the three questionnaire periods. The rest 
of the women reporting some alcohol use comprised the some-
times group.
The Child’s Father
Information about the father’s age was retrieved from the 
MBRN [31]. Information about education was self-reported by the 
mother, and information about symptoms of anxiety and depres-
sion was retrieved from the father questionnaire. Fathers also re-
ported on illegal drug use earlier in life, during the last 6 months 
before their partner became pregnant, and during the first 17/18 
weeks of the pregnancy. Fathers’ smoking during pregnancy was 
reported by both the father and the mother. The information was 
coded as “yes” if any of them reported smoking.
Analysis Strategy and Statistical Methods
The study population of pregnant women was divided into 3 
mutually exclusive groups according to self-reported use of can-
nabis:
1. Previous use: cannabis before pregnancy (lifetime and/or the 
last month before pregnancy, but not during pregnancy).
2. Curtailed use: cannabis during 1 period in pregnancy.
3. Prolonged use: cannabis during at least 2 periods in pregnancy.
Groups 2 and 3 could also include the use of cannabis before 
pregnancy. Potential confounders were identified a priori based on 
the published literature. We summarized and analyzed (χ2 analy-
sis) maternal and paternal characteristics for each of the 3 groups 
(Table 1). Mean values, standard deviations, and proportions for 
different birth outcomes for each of these 3 groups were calculated 
(Table 2). Descriptive analysis (linear regression and χ2 analysis) 
showed that there were statistically significant differences in the 
neonatal growth parameters (weight [p < 0.001], length [p = 0.008], 
and head circumference [p = 0.031]) between the 3 cannabis 
groups.
Based on the results from these analysis, linear regression was 
used to estimate adjusted effects of prenatal cannabis exposure on 
weight, length, and head circumference (Table 3). We adjusted for 
the following covariates: maternal age, education, parity, alcohol 
use during pregnancy, presence of symptoms of anxiety/depres-
sion, tobacco smoking in pregnancy, use of illicit drugs, use of pre-
scribed medications during pregnancy (opioids and benzodiaze-
pines), work situation, planned pregnancy, and sex. We did not 





Table 1. Parental characteristics by maternal use of cannabis before and during pregnancy. Participants of the 
Norwegian Mother and Child Cohort Study (N = 10,373 singleton pregnancies)
Group 1 Group 2 Group 3 p value
previous use of 
cannabis, but not used 
during pregnancy
cannabis use 1 period 
in pregnancy 
(short-term users)
cannabis use at least 
2 periods in pregnancy 
(long-term users)
n (%) n (%) n (%)
n 10,101 (97.4) 209 (2.0) 63 (0.6)
Maternal education, highera (N = 10,326)
No 3,567 (35.5) 119 (56.9) 37 (60.7) <0.001
Yes 6,579 (65.4) 90 (43.1) 24 (39.3)
Paternal education, higher (N = 9,991)
No 4,616 (47.4) 129 (67.2) 44 (73.3) <0.001
Yes 5,123 (52.6) 63 (32.8) 16 (26.7)
Maternal age in years (N = 10,316)
<25 1,608 (16.0) 77 (37.0) 20 (31.7) <0.001
25–29 3,477 (34.6) 70 (33.7) 24 (38.1)
30–34 3,604 (35.9) 39 (18.8) 12 (19.0)
≥35 1,356 (13.5) 22 (10.6) 7 (11.1)
Paternal age in years (N = 10,223)
<25 796 (8.0) 36 (17.6) 10 (15.9) <0.001
25–29 2,650 (26.6) 63 (30.7) 22 (34.9)
30–34 3,748 (37.7) 56 (27.3) 22 (34.9)
≥35 2,761 (27.7) 50 (24.9) 9 (14.3)
Planned pregnancy (N = 10,277)
No 2,895 (28.9) 113 (55.7) 35 (57.4) <0.001
Yes 7,118 (71.1) 90 (44.3) 26 (42.6)
Maternal tobacco smoking in pregnancy (N = 8,038)
No 6,315 (80.6) 81 (54.4) 15 (27.3) <0.001
Sometimes 1,039 (13.3) 46 (30.9) 20 (36.4)
Daily 480 (6.1) 22 (14.8) 20 (36.4)
Paternal tobacco smoking in pregnancy (N = 9,991)
No 6,015 (59.6) 64 (30.6) 13 (20.6) <0.001
Yes 4,086 (40.5) 128 (61.2) 47 (74.6)
Maternal use of illegal drugs (other than cannabis) (N = 6,106)
No 3,374 (57.0) 21 (14.7) 2 (4.4) <0.001
Yes, earlier to pregnancy 2,522 (42.6) 80 (55.9) 38 (84.4)
Yes, in pregnancy 22 (0.4) 42 (29.4) 5 (11.1)
Paternal use of illegal drugs (N = 7,662)
No 3,154 (42.1) 28 (22.4) 3 (6.4) <0.001
Yes, earlier 3,406 (45.5) 31 (24.8) 8 (17.0)
Yes, last 6 months before pregnancy 782 (10.4) 56 (44.8) 25 (53.2)
Yes, in pregnancy 148 (2.0) 10 (8.0) 11 (23.6)
Maternal alcohol intake in pregnancy (N = 10,183)
Never 2,997 (30.2) 41 (20.3) 12 (19.0) <0.001
Sometimes 4,373 (44.1) 82 (40.6) 23 (36.5)
Regularly/binge 2,548 (25.7) 79 (39.1) 28 (44.4)
Maternal analgesic opioids use in pregnancy (N = 10,373)
No 9,846 (97.5) 197 (94.3) 56 (88.9) <0.001
Yes 255 (2.5) 12 (5.7) 7 (11.1)
Maternal benzodiazepinesb use in pregnancy (N = 10,373)
No 9,924 (98.3) 193 (92.3) 57 (90.5) <0.001
Yes 177 (1.8) 16 (7.7) 6 (9.5)
Parity (N = 10,316)
0 5,753 (57.3) 156 (75.0) 35 (55.6) <0.001
1 3,156 (31.4) 33 (15.9) 19 (30.2)
≥2 1,136 (11.3) 19 (9.1) 9 (14.3)




tion between this variable and maternal symptoms of anxiety and 
depression during pregnancy. Neither did we include marital sta-
tus because the distribution between the two categories of this vari-
able was not consistent throughout the three cannabis groups. We 
used clustered robust variance estimators for 95% confidence in-
tervals to account for clustering among mothers with multiple 
pregnancies.
We examined the robustness of our findings in a set of addi-
tional analyses:
1. 41.1% of information about maternal use of other illegal sub-
stances and 22.5% of smoking information were missing. To 
account for missingness of these important confounders, we 
have performed multiple imputation using chained equations 
(mi impute chained command in STATA) and included the 
following covariates as potential predictors of the missing val-
ues: maternal age, education, parity, alcohol use during preg-
nancy, presence of symptoms of anxiety/depression, tobacco 
smoking in pregnancy, use of illicit drugs, use of prescribed 
medications during pregnancy (opioids and benzodiazepines), 
work situation, planned pregnancy, and sex. Combined results 
from 10 imputation sets are presented.
2. We used propensity scores to address imbalances in baseline con-
founder distributions between prolonged users and discontinu-
ers, and curtailed users and previous users, separately. In logistic 
regression models, we estimated the probability of using cannabis 
in pregnancy (separately for short- and long-term use), condi-
tional on the confounders used in adjusted models described 
above. We used inverse probability of treatment weighting 
(IPTW) approaches based on the propensity score to estimate the 
average effect of cannabis and assessed the balance of baseline 
characteristics in the weighted population using the standardized 
mean difference, with 0.15 as a cutoff for evidence of imbalance. 
In a rare case, when we were not able to achieve <0.15 standard-
ized mean difference between covariates in weighted populations, 
the covariates were added to a final weighted model.
3. Not all pregnancies had information from both parents. Addi-
tional analyses were performed in the pregnancies, which also 
included paternal information. In these analyses, the character-
istics of the father were also included as confounders in the 
adjusted analysis.
Statistical analyses were conducted using SPSS for Windows, 
20.0; SPSS Inc., Chicago, IL, and STATA 14.
Group 1 Group 2 Group 3 p value
previous use of 
cannabis, but not used 
during pregnancy
cannabis use 1 period 
in pregnancy 
(short-term users)
cannabis use at least 
2 periods in pregnancy 
(long-term users)
n (%) n (%) n (%)
Marital status (N = 10,316)
Married or living with partner 9,235 (91.9) 161 (77.4) 55 (87.3) <0.001
Others 810 (8.1) 47 (22.6) 8 (12.3)
Maternal BMI (N = 10,133)
<25 7,304 (74.0) 147 (73.9) 54 (85.7) 0.530
25–29 1,834 (18.6) 36 (18.1) 7 (11.1)
30–34 528 (5.4) 12 (6.0) 2 (3.2)
≥35 205 (2.1) 4 (2.0) 0 (0)
Maternal depression before pregnancyc (N = 10,001)
No 8,529 (87.7) 178 (89.0) 45 (73.8) <0.001
Yes 1,201 (12.3) 22 (11.0) 16 (26.2)
Maternal symptoms of anxiety and depression during pregnancyd (N = 9,216)
No 7,100 (79.1) 112 (63.3) 31 (50.0) <0.001
Yes, short term 1,381 (15.4) 43 (24.3) 17 (27.4)
Yes, long term 496 (5.5) 22 (12.4) 14 (22.6)
Paternal symptoms of anxiety and depression during pregnancyc (N = 8,643)
No 8,092 (95.5) 111 (88.1) 39 (86.7) <0.001
Yes 380 (4.5) 15 (11.9) 6 (13.3)
Working status (N = 10,322)
Working 9,022 (89.8) 159 (76.4) 48 (77.4) <0.001
Not working 718 (7.1) 35 (16.8) 10 (16.1)
Disability pensioner 143 (1.4) 7 (3.4) 4 (6.5)
Others 169 (1.7) 7 (3.4) 0 (0)
a Completed or on-going college or university degree. b Benzodiazepines and benzodiazepines-like (a class of drugs 
with similar pharmacodynamics and different chemical structures to benzodiazepines) drugs. c Assessment was done 
in week 17–18. d Symptoms of anxiety and depression were assessed in pregnancy weeks 17–18 or 30 (short term) or 







Table  1 shows baseline maternal characteristics ac-
cording to cannabis use before and during pregnancy. In 
total, 10,101 women reported cannabis use before preg-
nancy (previous use) and 272 women reported cannabis 
use during pregnancy. In 209 of pregnancies, the woman 
had used cannabis during only 1 period (curtailed use), 
while use in at least 2 periods was reported in 63 pregnan-
cies (prolonged use).
Table 2. Descriptive statistics for cannabis use and birth outcome among participants in the Norwegian Mother and Child Cohort Study 
(MoBa)
Use of cannabis
group 1 group 2 group 3
previous use of cannabis, but 
not used during pregnancy, 
n = 10,101
cannabis use 1 period in 
pregnancy only (curtailed use), 
n = 209
cannabis use at least 2 periods 
in pregnancy (prolonged use), 
n = 63
Birth weight, g, mean (SD) 3,564 (588) 3,449 (560) 3,377 (438)
Birth length, cm, mean (SD) 50.2 (2.8) 49.7 (2.7) 49.7 (2.9)
Head circumference, cm, mean (SD) 35.2 (1.9) 35.0 (1.9) 34.7 (1.2)
Gestational length, week, mean (SD) 39.5 (2.3) 39.3 (2.7) 39.2 (1.6)
Apgar score, 1 min, mean (SD) 8.6 (1.3) 8.5 (1.8) 8.6 (1.5)
Apgar score, 5 min, mean (SD) 9.4 (1.0) 9.3 (1.4) 9.4 (1.0)
Placements in neonatal intensive care unit, n (%) 764 (7.9) 23 (11.9) 5 (8.1)
Preterm birth, n (%) 528 (5.3) 18 (8.7) 4 (6.3)
Malformation, n (%) 524 (5.2) 11 (5.3) 4 (6.3)
Small for gestational age, n (%) 218 (2.2) 4 (1.9) 1 (1.6)
SD, standard deviation.
Table 3. Linear regression models for birth weight, head circumference, and birth length outcomes predicted by cannabis exposure 
during pregnancy
Curtailed use versus previous use of 
cannabis, but not used during pregnancya
Prolonged use versus previous use of 
cannabis, but not used during pregnancyb
B 95% CI p value B 95% CI p value
Birth weight
Cannabis in pregnancy – unadjustedc −57 −166 to 53 0.31 −334 −507 to −160 <0.001
Cannabis in pregnancy – adjustedd 12 −88 to 112 0.82 −228 −354 to −102 <0.001
Birth length
Cannabis in pregnancy – unadjustedc −0.5 −0.9 to 0.0 0.07 −1.0 −1.8 to −0.2 0.01
Cannabis in pregnancy – adjustedd −0.1 −0.7 to 0.5 0.75 −0.5 −1.6 to 0.6 0.41
Head circumference
Cannabis in pregnancy – unadjustedc −0.1 −0.4 to 0.3 0.74 −0.6 −1.2 to –0.1 0.03
Cannabis in pregnancy – adjustedd 0.2 −0.2 to 0.5 0.30 −0.4 −0.8 to 0.1 0.07
a N = 4,981 for birth weight; N = 4,797 for birth length; N = 4,895 for head circumference. b N = 4,922 for birth weight; N = 4,736 
for birth length; N = 4,838 for head circumference. c The crude regression analyses were restricted to the same study sample as in the 
adjusted analysis. d Adjusted for a set of confounders: maternal age, education, parity, alcohol use during pregnancy (never, sometimes, 
and regular/binge), presence of symptoms of anxiety/depression, tobacco smoking in pregnancy (never, sometimes, and daily), use 
of illicit drugs, use of prescribed medications during pregnancy (opioids and benzodiazepines), work situation, planned pregnancy, 
and sex.





The proportion of women with higher education was 
markedly higher in the group of women who only used 
cannabis before pregnancy (65.4%) and a similar pattern 
was seen for fathers (52.6%) (Table 1). In addition, the 
majority (71.1%) of pregnancies in this group were 
planned, in contrast to low proportions of planned preg-
nancies among women with curtailed cannabis use 
(44.3%) and with prolonged cannabis use (42.6%) during 
pregnancy.
Women who used cannabis during pregnancy were 
more likely to use other illegal and prescribed drugs dur-
ing pregnancy and to have partners with a similar pattern 
of drug use. These women were also more likely to smoke 
while pregnant, a lower proportion who abstained from 
drinking during pregnancy, and the proportion of binge 
drinking was higher, compared to women who used can-
nabis before pregnancy.
The proportion of women who reported depression 
before to pregnancy was high in all the cannabis groups. 
Women who used cannabis during pregnancy were more 
likely to report long-term symptoms of depression or 
anxiety during pregnancy than women who did not 
(12.4–22.6% vs. 5.5%, respectively).
Birth Outcomes
In Table 2 we present descriptive statistics of birth out-
comes according to different cannabis groups. There was 
a gradual reduction in mean values of birth weight, head 
circumference, and birth length from the group of wom-
en who only used cannabis before pregnancy to the group 
with curtailed use and further to the group with pro-
longed use (Table 2). There were no clear patterns for the 
other birth outcomes.
Table 3 shows the results of linear regression analysis 
on the growth parameters for short-term and long-term 
cannabis use during pregnancy. Unadjusted and adjusted 
analyses suggest unlikely effects of short-term exposure 
on birth weight, length, and head circumference. For 
long-term use, our data support the effect on all growth 
parameters in unadjusted analyses, but after adjustment, 
the only statistically significant effect was on birth weight 
(B = −228 g, p < 0.001).
The observed effects of prolonged cannabis use on 
the birth weight of the newborn stayed consistent where 
we accounted for missingness (Table  4) and when we 
used IPTW approaches (Table 5). Results were also sim-
ilar for the subgroup of women where information about 
the child’s father was available (Table 6). When infor-
mation about the father was included in combination 
with maternal characteristics in the analysis, prolonged 
cannabis use showed effects on birth weight in the same 
order of magnitude as when only maternal characteris-
tics were included in the adjusted analysis (B = −225 g, 
p = 0.01). An effect on birth length was also observed in 
children of women with prolonged use (B = −1.4, p = 
0.01) (Table 6).
Table 4. Linear regression models for birth weight, head circumference, and birth length outcomes predicted by 
cannabis exposure during pregnancy
Prolonged use versus previous use of cannabis, but 
not used during pregnancy
B 95% CI p value
Birth weight
Cannabis in pregnancy – adjusted −153 −262 to −42 0.01
Birth length
Cannabis in pregnancy – adjusted −0.3 −1.1 to 0.5 0.47
Head circumference
Cannabis in pregnancy – adjusted −0.3 −0.7 to 0.0 0.05
Multiple imputation on variables tobacco smoking and use of illicit drugs during pregnancy used. N = 8,652 
for birth weight; N = 8,332 for birth length; N = 8,509 for head circumference. Adjusted for a set of confounders: 
maternal age, education, parity, alcohol use during pregnancy (never, sometimes, and regular/binge), presence 
of symptoms of anxiety/depression, tobacco smoking in pregnancy (never, sometimes, and daily), use of illicit 







In this study, children of mothers reporting curtailed 
cannabis use during pregnancy did not display any of the 
studied adverse birth outcomes when compared to previ-
ous users of cannabis and after adjustment for relevant 
confounders. However, after maternal prolonged canna-
bis use, children had a lower mean birth weight of ap-
proximately 200 g, even after adjusting for important 
confounders as for instance smoking.
The association between prolonged maternal use of 
cannabis during pregnancy and lower birth weight is in 
accordance with the recent meta-analysis [15]. The re-
duction in birthweight observed in the present study 
linked with cannabis use was estimated to be approxi-
mately 200 g, which was in the same order of magnitude 
Table 5. Linear regression models for birth weight, head circumference, and birth length outcomes predicted by 
cannabis exposure during pregnancy
Prolonged use versus previous use of cannabis, but 
not used during pregnancy
B 95% CI p value
Birth weight
Cannabis in pregnancy – adjusted −369 −517 to −220 <0.001
Birth length
Cannabis in pregnancy – adjusted 2.9 −3.3 to 9.2 0.93
Head circumference
Cannabis in pregnancy – adjusted −0.6 −1.5 to 0.4 0.25
The propensity score based on maternal characteristics, IPTW approaches used. N = 4,922 for birth weight; 
N = 4,736 for birth length; N = 4,838 for head circumference. Adjusted for a set of confounders: maternal age, 
education, parity, alcohol use during pregnancy (never, sometimes, and regular/binge), presence of symptoms of 
anxiety/depression, tobacco smoking in pregnancy (never, sometimes, and daily), use of illicit drugs, use of 
prescribed medications during pregnancy (opioids and benzodiazepines), work situation, planned pregnancy, 
and sex. IPTW, inverse probability of treatment weighting.
Table 6. Linear regression models for birth weight, head circumference, and birth length outcomes predicted by 
prolonged cannabis exposure during pregnancy
Prolonged use versus previous use of cannabis, but 
not used during pregnancy
B 95% CI p value
Birth weight
Cannabis in pregnancy – adjusteda −225 −387 to −63 0.01
Birth length
Cannabis in pregnancy – adjusteda −1.4 −2.3 to −0.4 0.01
Head circumference
Cannabis in pregnancy – adjusteda −0.5 −1.1 to 0.2 0.14
Adjustment based on maternal and paternal characteristics. N = 3,710 for birth weight; N = 3,573 for birth 
length; N = 3,648 for head circumference. aAdjusted for a set of confounders: maternal and paternal age and 
education, parity, alcohol use during pregnancy (never, sometimes, and regular/binge), presence of symptoms 
of anxiety/depression, maternal (never, sometimes, and daily) and paternal tobacco smoking in pregnancy, 
maternal and paternal use of illicit drugs, use of prescribed medications during pregnancy (opioids and 
benzodiazepines), work situation, planned pregnancy, and sex.




as what has been reported in tobacco smoking women 
[32].
Previous reviews regarding birth length have shown 
conflicting results [15–17]. Our results were not in line 
either. We only observed reduced birth length in the 
smaller subgroup of pregnant women who had a partner 
who filled in and returned the father’s questionnaire 
making it possible to include paternal characteristics in 
the analysis. Probably, this population has a better socio-
economic status than women living without partners, and 
we would expect this group to have fewer other unmea-
sured confounders that could contribute to reduced birth 
length. Since this is a smaller and more selected group of 
individuals, it might, however, be problematic to general-
ize this finding. Another possible explanation of a small-
er effect on length could be that measurement error might 
be a greater problem when measuring length than weight. 
Thus, we cannot rule out a possible effect of cannabis also 
on birth length.
Less than 1% of the women in the study reported can-
nabis use during pregnancy. Studies from other countries 
find higher figure [4, 14]. Norwegian women were less 
likely to use cannabis during pregnancy, or they may have 
underreported their use. There is, however, the possibil-
ity that the participants represent a selected group with 
higher socioeconomic status and more health-literate be-
havior compared to pregnant women in Norway in gen-
eral [33].
Women reporting cannabis use during pregnancy had 
lower socioeconomic status, used more alcohol, tobacco, 
and prescribed drugs, and had more psychiatric symp-
toms compared to women using cannabis before but not 
during pregnancy. This illustrates the importance of ad-
justing for all possible confounders that could influence 
outcome. Clustering of risk by concurrent tobacco, alco-
hol, and cannabis use in pregnancy is in agreement with 
previous studies [12, 34, 35]. Specifically, concomitant to-
bacco use with maternal cannabis use may be attributable 
to increased adverse birth outcomes and less attributable 
to cannabis alone [20].
Methodological Consideration
A major strength of this population-based study is the 
size of the cohort and that the risk of recall bias is mini-
mized by the prospective design. Response to detailed 
questions regarding lifestyle and health-related and so-
ciodemographic factors allowed adjusting for important 
potential confounders. We could adjust for paternal char-
acteristics in the analysis. Information about cannabis use 
both before and during pregnancy was particularly im-
portant since this made it possible to distinguish between 
effects of cannabis use during pregnancy as such and the 
effects of unmeasured characteristics of the women using 
cannabis.
The findings should, however, be interpreted with 
some caution. Firstly, the data on cannabis use were based 
on self-report, and the questions on illegal drug use have 
not been validated. In other cohorts, the correspondence 
between pregnant women’s self-reporting of cannabis use 
and samples of their urine or meconium of their children 
varies [36–39]. However, any underreporting is expected 
to have a marginal effect on the risk estimates, as high 
specificity is more important than sensitivity when the 
prevalence is low [40]. Underreporting of tobacco smok-
ing is common [41] and may have bias association. A val-
idation study of MoBa compared plasma cotinine with 
self-reported tobacco smoking and concluded that self-
reported tobacco use is a valid marker for use [42]. This 
also suggests that MoBa participants in fact report risk 
behavior, suggesting the validity of the cannabis use mea-
sures as well.
We lack information on potency/dose and frequency 
of cannabis use as well as precise information on the du-
ration of cannabis use. Pregnant women reporting cur-
tailed cannabis use (in one period) might, in theory, have 
used more cannabis or over a more extended period than 
those who report prolonged use, that is, use in two or 
more periods. However, women reporting prolonged use 
during pregnancy are more likely to report using canna-
bis to manage mood, stress, and morning sickness [38, 
39], supporting the idea that they were likely to have con-
sumed more cannabis over time.
The selection of individuals into the MoBa cohort may 
have introduced bias. Participants in MoBa have been 
shown to have a healthier lifestyle than the general preg-
nant population in Norway [33]; for instance, they report 
lower use of prescribed drugs with abuse potential com-
pared to the whole pregnant population [43, 44]. This 
may also suggest that MoBa participants are less likely to 
use cannabis than the general pregnant population. How-
ever, a relatively homogeneous population with a healthy 
lifestyle may prove an advantage when assessing associa-
tions since unmeasured confounding is probably re-
duced.
Cannabis is the most commonly used illegal psychoac-
tive substance, and many young adults have experience 
with the drug. Rates of cannabis use among pregnant 
women are increasing [4]. Healthcare providers have an 
important opportunity to address prenatal cannabis use 





Future research on long-term outcomes is necessary. 
A challenge to such studies is attrition, and thus cohorts 
need to heavily invest in reducing participant loss. A pos-
sible solution to this challenge is using nationwide regis-
tries that are well suited for longitudinal studies [45–47].
Implications
This study indicates that long-term cannabis use in 
pregnancy results in reduced birth weight of the newborn, 
a worrying effect since low birth weight may have negative 
at-birth as well as long-term consequences for the child, 
such as a risk factor of neonatal and infant death, develop-
ment of chronic disease, and growth and cognitive disor-
ders [48, 49]. Pregnant women and those considering be-
coming pregnant should be advised to avoid using canna-
bis. Clinicians should screen not only for cannabis use but 
also for the length and intensity of use as part of a com-
prehensive substance use screening. In addition, pregnant 
women should be advised that cutting down the use of 
cannabis during pregnancy is beneficial as opposed to 
continuous use of cannabis while pregnant.
Conclusion
This study provides evidence of a clinically relevant as-
sociation between prolonged maternal use of cannabis 
during pregnancy and reduced birth weight of the new-
born. The weight reduction observed was in the same or-
der of magnitude as what has been reported for tobacco 
smoking during pregnancy. The results may indicate that 
use over time is necessary to cause harm. These results 
add to the growing body of evidence of reduced birth 
weight following cannabis use in pregnancy.
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